Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3818.74% is 36% above its 1-year average of -5976.48%, near the high end of its 1-year range (-8134.22%–-3818.74%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-3818.74%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tenaya Therapeutics, Inc.
Market Cap
$118.59M
EBITDA Margin
-3818.74%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.83M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
Market Cap
$117.76M
EBITDA Margin
-1142.44%
TTM Avg
-828.55%
3Y Avg
-828.55%
5Y Avg
-828.55%
Market Cap
$119.84M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
Market Cap
$120.41M
EBITDA Margin
-445.98%
TTM Avg
-559.71%
3Y Avg
-600.34%
5Y Avg
-1391.92%
Market Cap
$116.76M
EBITDA Margin
-121.55%
TTM Avg
-120.84%
3Y Avg
-101.07%
5Y Avg
-82.00%
Market Cap
$115.67M
EBITDA Margin
-254.86%
TTM Avg
-347.69%
3Y Avg
-398.28%
5Y Avg
-4102.41%
Market Cap
$122.43M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | $118.59M | -3818.74% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -475.96% | -475.96% | -272.89% | -272.89% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -1142.44% | -828.55% | -828.55% | -828.55% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| Seer, Inc. (SEER)vs › | $120.41M | -445.98% | -559.71% | -600.34% | -1391.92% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -121.55% | -120.84% | -101.07% | -82.00% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -254.86% | -347.69% | -398.28% | -4102.41% |
| BGM Group Ltd. (BGM)vs › | $122.43M | -29.32% | -13.32% | -6.17% | -1.07% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -944.37% | -1132.38% | -1244.49% | -1244.49% |
Gross Margin
0.0%
EBITDA Margin
-3818.7%
Operating Margin
0.0%
Net Margin
-7724.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3818.74% |
| 2026-03-31 | -8134.22% |
